Workflow
Online SPE液相色谱系统
icon
Search documents
「科诺美」获数千万元投资,加速超高效液相色谱系统“国产替代”|36氪首发
3 6 Ke· 2026-02-24 00:02
Core Insights - Chromai has completed a strategic financing round of several tens of millions of RMB, exclusively funded by the Beijing Pharmaceutical and Health Industry Investment Fund, aimed at expanding operations and accelerating market layout [1] - The company has previously secured nearly 100 million RMB in investments from various capital firms and recently completed a multi-million A+ round financing from Nine安 Medical [1] - Founded in 2019, Chromai specializes in the research and industrialization of high-end liquid chromatography, achieving full independent research and development of ultra-high-performance liquid chromatography (UHPLC) systems [1][2] Company Developments - Chromai's Frontier series UHPLC system features a design capable of withstanding pressures of 22,000 PSI, enhancing both separation speed and detection sensitivity [2] - The product matrix includes the Leaps series, which focuses on practical efficiency and cost-effectiveness, and has led to significant sales growth [2] - The company has developed the EyouLab intelligent chromatography data management system, integrating AI algorithms for compliance with industry standards [2] Market Position and Strategy - Chromai is addressing specific industry needs with customized solutions, such as a two-dimensional preparation solution for the biopharmaceutical sector and an automated online SPE liquid chromatography system for environmental monitoring [3] - The company officially launched commercial operations in 2023, with its products and services now available in over 20 countries, and overseas revenue steadily increasing as a percentage of total revenue [3] Leadership and Investment - The CEO of Chromai emphasizes the commitment to high-end liquid chromatography and the importance of continuous technological innovation and market recognition [4] - The Beijing Pharmaceutical and Health Industry Investment Fund focuses on supporting high-growth companies with core technological advantages in key sectors like biomedicine and high-end medical devices [5]